MGME1

Across TCGA pan-cancer cohorts, MGME1 mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated MGME1 data layer compared with 25 for mass-spec protein and 1 for mutation status.

The strongest signal is observed in lung squamous cell carcinoma (LSCC), where higher MGME1 mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated MGME1 expression acts as an unfavorable survival marker, although some lineages such as LSCC and GBM show a favorable association.

LSCC, PDAC, and CCRCC are the cancer types where MGME1 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LSCC	DFS	Median	II,III,IV	0.872	0.530	<.001	38	view →
PDAC	DFS	Median	III,IV	0.298	0.706	.004	17	view →
CCRCC	DFS	Median	II,III,IV	0.462	0.737	.011	8	view →
GBM	OS	Median	All	0.519	0.273	.027	4	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

MGME1–LSCC (DFS)

Open the LSCC breakdown →